Keyword Analysis & Research: cd38 adc

biomedcentral.com

https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02421-2

DA: 79 PA: 36 MOZ Rank: 74

ashpublications.org

https://ashpublications.org/blood/article/134/Supplement_1/5621/425467/Preclinical-Development-of-an-Anti-CD38-Antibody

DA: 59 PA: 65 MOZ Rank: 71

ashpublications.org

https://ashpublications.org/blood/article/134/Supplement_1/5621/425467/Preclinical-Development-of-an-Anti-CD38-Antibody

WEBNov 13, 2019 · The ADC showed specific activity towards CD38-expressing tumors but was less active against CD38-expressing normal PBMC cells, which express relatively … Author: Lingna Li, Wenyong Tong, Megan Lau, Katherine Fells, Tong Zhu, Yingqing Sun, Ernest Kovacs, Alisher ... Publish Year: 2019

Author: Lingna Li, Wenyong Tong, Megan Lau, Katherine Fells, Tong Zhu, Yingqing Sun, Ernest Kovacs, Alisher ...

Publish Year: 2019

DA: 82 PA: 48 MOZ Rank: 29

explorationpub.com

https://www.explorationpub.com/Journals/etat/Article/100267

WEBJan 14, 2022 · Some of these antibody targets include B cell maturation antigen (BCMA), cluster of differentiation 38 (CD38), CD46, CD74, CD56, and CD138 . The mechanism …

DA: 46 PA: 67 MOZ Rank: 81

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728650/

WEBDec 5, 2023 · ADC: STI-6129 (also CD38-077) Exhibits CD38-dependent cytotoxic activity against a panel of CD38-expressing tumor cell lines : Radioimmunotherapy: …

DA: 45 PA: 29 MOZ Rank: 90

nature.com

https://www.nature.com/articles/s41392-022-00947-7

WEBMar 22, 2022 · Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. ... to an …

DA: 31 PA: 66 MOZ Rank: 48

biomedcentral.com

https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02421-2

WEBJun 28, 2022 · CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. The high expression of CD38 …

DA: 44 PA: 8 MOZ Rank: 56

clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT05519527

WEBAug 29, 2022 · Brief Summary: This is an open-label, phase 1b/2 trial. It is designed to identify the recommended phase 2 dose (RP2D) of STI-6129, and the safety and efficacy …

DA: 64 PA: 35 MOZ Rank: 20

sciencedirect.com

https://www.sciencedirect.com/science/article/pii/S0006497118635475

WEBNov 13, 2019 · In summary, CD38-077 exhibits strong anti-tumor activity in vitro and in vivo. The ADC showed specific activity towards CD38-expressing tumors but was less active …

DA: 30 PA: 24 MOZ Rank: 16

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734206/

WEBNov 30, 2020 · Depending on the disease type, immune cell population, or animal model analyzed, several reports indicate that CD38 can either suppress or induce …

DA: 35 PA: 13 MOZ Rank: 88

nih.gov

https://pubmed.ncbi.nlm.nih.gov/30594452/

WEBFeb 1, 2019 · Dara-DM4 showed significantly higher cellular uptake and inhibitory efficacy on MM1S cells that overexpressing CD38 with an IC 50 of 0.88 µg/mL post 72 hr …

DA: 46 PA: 31 MOZ Rank: 36

ashpublications.org

https://ashpublications.org/blood/article/138/Supplement%201/4763/481786/A-Phase-1-Open-Label-Dose-Escalation-Study-of-the

WEBNov 5, 2021 · STI-6129 binds to different CD38 epitopes than daratumumab. Upon binding to CD38, STI-6129 ADC is internalized by the cancer cell and undergoes lysosomal …

DA: 46 PA: 30 MOZ Rank: 2